1. High yield production of human invariant chain CD74 constructs fused to solubility-enhancing peptides and characterization of their MIF-binding capacities.
- Author
-
Kok T, Wasiel AA, Dekker FJ, Poelarends GJ, and Cool RH
- Subjects
- Amino Acids genetics, Animals, Antigens, Differentiation, B-Lymphocyte chemistry, Antigens, Differentiation, B-Lymphocyte genetics, Endoplasmic Reticulum genetics, Escherichia coli genetics, Fasciola hepatica chemistry, Golgi Apparatus genetics, HLA-DR Antigens chemistry, HLA-DR Antigens genetics, Histocompatibility Antigens Class II chemistry, Histocompatibility Antigens Class II genetics, Humans, Intramolecular Oxidoreductases chemistry, Intramolecular Oxidoreductases genetics, Macrophage Migration-Inhibitory Factors chemistry, Macrophage Migration-Inhibitory Factors genetics, Peptides genetics, Protein Binding, Solubility, Antigens, Differentiation, B-Lymphocyte isolation & purification, Histocompatibility Antigens Class II isolation & purification, Intramolecular Oxidoreductases isolation & purification, Macrophage Migration-Inhibitory Factors isolation & purification, Peptides chemistry
- Abstract
The HLA class II histocompatibility antigen gamma chain, also known as HLA-DR antigen-associated invariant chain or CD74, has been shown to be involved in many biological processes amongst which antigen loading and transport of MHC class II molecules from the endoplasmic reticulum to the Golgi complex. It is also part of a receptor complex for macrophage migration inhibitory factor (MIF), and participates in inflammatory signaling. The inhibition of MIF-CD74 complex formation is regarded as a potentially attractive therapeutic target in inflammation, cancer and immune diseases. In order to be able to produce large quantities of the extracellular moiety of human CD74, which has been reported to be unstable and protease-sensitive, different constructs were made as fusions with two solubility enhancers: the well-known maltose-binding domain and Fh8, a small protein secreted by the parasite Fasciola hepatica. The fusion proteins could be purified with high yields from Escherichia coli and were demonstrated to be active in binding to MIF. Moreover, our results strongly suggest that the MIF binding site is located in the sequence between the transmembrane and the membrane-distal trimerisation domain of CD74, and comprises at least amino acids 113-125 of CD74., (Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF